This health-care REIT, MLP, and oil-services firm stand out as relative bargains in today's richly valued market, says Morningstar's Matt Coffina.
Looking past volatile trade and inventory data, we see upside for consumer and business spending in the second half, says Morningstar's Bob Johnson.
Plus, Buffett burnishes a fast-food deal, Tiffany investors pay a premium, and more.
Kinder's reorganization brings upside potential, but even after the change, its payout coverage is too thin for conservative income investors, says Morningstar DividendInvestor editor Josh Peters.
Although a drawdown in the short term is a real possibility, investors should still see a 4.5% to 6% real return over the long run, says Morningstar's Matt Coffina.
Facing entrenched structural issues, the eurozone's days of robust growth are likely over, but there are some reasons for hope, says Morningstar's Bob Johnson.
Plus, an under-the-radar retailer looks undervalued, B of A stays under scrutiny, and rate hike talk heats up.
Plus, the difference a moat makes in retail, the long view on Cisco, and more.
In a fully valued market, there are worse things than buying wide-moat names at decent discounts.
Investors concerned with Express Scripts' integration of Medco are overlooking the firm's long-term potential to benefit from an increased focus on health-care cost-cutting, says Morningstar StockInvestor editor Matt Coffina.